Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc > Financing done at 11.6 cents pre-consolidation numbers

<< Previous

Bullboard Posts

Next >>

Comment by Cotitwoon Sep 28, 2017 7:48am

110 Views

Post# 26752242

RE:RE:RE:Financing done at 11.6 cents pre-consolidation numbers

I believe they all did. I think it was published on Sedar September 23-24.John Drake $100k
Alison $50K Directors Gene Kelly $10K.and there is the second traunch as well

<< Previous

Bullboard Posts

Next >>

Three micro-cap value stocks trading at peak pessimism